Why we exist
More yearsto do whatmatters.
Driessen-Kerr exists to bring applied science and access closer together, working to expand the possibility of living longer with health, autonomy and participation.
An approach to designing mRNA product systems by considering payload, composition, process, quality and transfer together for each application.
Driessen-Kerr brings together applied science, mRNA product systems and scale-oriented design through its NM-mRNA approach. Payload, composition, process and transfer are considered together to bring innovation closer to access. Explore the architecture and discuss your application.
Scale to reach people.
NM-mRNA is Driessen-Kerr's approach connecting payload selection, composition, process, quality attributes, stability, analytics and transfer. Each decision is considered within the product system and its application.
The ambition of access at continental scale guides product and process design. Application, technical criteria and partnership terms are explored in institutional dialogue.
Architecture and transfer →From need to evidence: four questions guide the design and assessment of each program.
The full technical architecture — from payload and composition to process, stability and evidence criteria — is detailed on the platform page. View the architecture →
From Hypothesis to Physical System.
A program's value lies not just in molecule selection. It lies in the method that connects that molecule to the decisions that must be tested: formulation stability, release, and process scalability.
Each program should feed a shared matrix of hypotheses, critical attributes, process decisions, and next proof. Learning remains comparable without anticipating product performance.
Compatible Composition
Compatibility mapping between mRNA payload and excipients to guide delivery testing.
Critical Characterization
Definition of measurable Critical Quality Attributes (CQA) prior to in vivo evidence generation.
Translational Scale
Scale-oriented design; transfer, stability and comparability to be qualified.
Evidence Classification
Discrimination between ingredient literature evidence vs. closed-system validation.
From Science to Product.
Driessen-Kerr connects molecular knowledge, formulation engineering and product criteria in a technical conversation shaped around each partner's context.
→ Public-domain knowledge supported by published literature. It provides direction but does not replace formulation characterization.
→ An integrated view of composition, critical attributes, process and transfer criteria for each application.
→ Methods and evaluation criteria are defined according to the product, population and collaboration objective.
The NutritionalSurface.
EPITIDE™ is Driessen-Kerr's precision-nutrition program, distinct from NM-mRNA. Its architecture brings together ingredients, composition and formulation science in a dedicated conversation with nutrition and distribution partners.
A common product discipline.
NM-mRNA and EPITIDE™ are separate programs, with distinct compositions, objectives and evidence. They share a development discipline—composition design, critical-attribute selection, traceability, stability, process, evidence interpretation and cumulative learning—without either validating the other.
EPITIDE™ is a nutritional program without mRNA. Its criteria and evidence are distinct and do not validate NM-mRNA.
Next Action.
We build partnership discussions around the technical objective, relevant evidence and collaboration scope. Choose the route that fits your context.
Translational Platform
The NM-mRNA approach connects payload, composition, process and transfer. Discuss applications and technical criteria relevant to your organization.
Mechanistic Science
Documentation for the scientific community strictly separating published isolated ingredient mechanisms from formulation empirical evidence.
Partnerships & Mfg
An institutional discussion to define diligence scope, regulatory needs and which verifiable materials are available to share.
One starting point. Share your organization, goal and area of interest. The team will review the fit and indicate the next step by email, according to scope.
Choose a partnership route →